Here are the 10-K annual reports from Arbutus Biopharma Corporation (ABUS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ABUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABUS filings page.
Arbutus Biopharma Corporation is a clinical-stage biotech focused on chronic hepatitis B, developing imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company’s LNP delivery technology underpins major COVID-19 mRNA vaccines and is central to its strategy.
A key development is a settlement with Moderna, under which Moderna will pay an aggregate $950.0 million noncontingent lump sum to Arbutus and Genevant by July 8, 2026, plus a contingent lump sum of up to $1.3 billion tied to a limited appeal outcome. Arbutus is entitled to 20% of settlement proceeds (after litigation costs) under its Genevant license and also owns about 16% of Genevant’s common equity. The company is evaluating a potential return of capital to shareholders in the third quarter of 2026 after receiving its share of the noncontingent payment.
Arbutus continues patent litigation against Pfizer/BioNTech over alleged use of its LNP technology. It has restructured heavily, halting discovery efforts, closing its Warminster headquarters, and reducing its workforce by about 40% in 2024 and a further 57% in early 2025, incurring $12.9 million in one-time restructuring charges but significantly lowering net cash burn. As of June 30, 2025, non‑affiliate equity had an approximate market value of $472,133,611 based on a share price of $3.09, and as of March 18, 2026, there were 195,478,068 common shares outstanding.